Trexbio Inc., A Discovery Stage Company Decoding Tissue Immune Biology To Create Revolutionary Therapeutics, Today Announced That It Has Entered Into A Multi-Year Research Collaboration And Licensing Agreement With Janssen Pharmaceutica Nv, One Of The Janssen Pharmaceutical Companies Of Johnson & Johnson. This Collaboration With Janssen Research & Development Llc Will Focus On The Discovery Of Novel Tissue-Targeted Therapeutics Using Trexbio
